Keller-Stanislawski B - Search Results

1

The development of standardized case definitions and guidelines for adverse events following immunization.

Kohl KS, Gidudu J, Bonhoeffer J, Braun MM, Buettcher M, Chen RT, Drammeh B, Duclos P, Heijbel H, Heininger U, Hummelman E, Jefferson T, Keller-Stanislawski B, Loupi E, Marcy SM. Kohl KS, et al. Vaccine. 2007 Aug 1;25(31):5671-4. doi: 10.1016/j.vaccine.2007.02.063. Epub 2007 Mar 12. Vaccine. 2007. PMID: 17400339 No abstract available.

2

Pharmacokinetics of nicotine and cotinine after application of two different nicotine patches under steady state conditions.

Keller-Stanislawski B, Caspary S. Keller-Stanislawski B, et al. Arzneimittelforschung. 1992 Sep;42(9):1160-2. Arzneimittelforschung. 1992. PMID: 1445487

3

Transdermal nicotine in smoking cessation and involvement of non-specific influences.

Merz PG, Keller-Stanislawski B, Huber T, Woodcock BG, Rietbrock N. Merz PG, et al. Int J Clin Pharmacol Ther Toxicol. 1993 Oct;31(10):476-82. Int J Clin Pharmacol Ther Toxicol. 1993. PMID: 8262685 Clinical Trial.

4

[Pharmacokinetics of low-dose isosorbide dinitrate and metabolites after buccal or oral administration].

Keller-Stanislawski B, Marschner JP, Rietbrock N. Keller-Stanislawski B, et al. Arzneimittelforschung. 1992 Jan;42(1):17-20. Arzneimittelforschung. 1992. PMID: 1586374 Clinical Trial. German.

5

Pharmacokinetics of nicotine after application of a 30 cm2 nicotine patch under steady-state conditions.

Caspary S, Keller-Stanislawski B, Huber T, Merz PG. Caspary S, et al. Int J Clin Pharmacol Ther Toxicol. 1991 Mar;29(3):92-5. Int J Clin Pharmacol Ther Toxicol. 1991. PMID: 2071260

6

[Bioavailability of two slow-release formulations of verapamil].

Keller-Stanislawski B, Rietbrock N. Keller-Stanislawski B, et al. Arzneimittelforschung. 1990 Oct;40(10):1086-8. Arzneimittelforschung. 1990. PMID: 2291745 Clinical Trial. German.

7

Reactions of human keratinocytes in vitro after application of nicotine.

Theilig C, Bernd A, Ramirez-Bosca A, Görmar FF, Bereiter-Hahn J, Keller-Stanislawski B, Sewell AC, Rietbrock N, Holzmann H. Theilig C, et al. Skin Pharmacol. 1994;7(6):307-15. doi: 10.1159/000211311. Skin Pharmacol. 1994. PMID: 7524565

8

Anaphylactic reactions after COVID-19 vaccination in Germany.

Barth I, Weißer K, Gaston-Tischberger D, Mahler V, Keller-Stanislawski B. Barth I, et al. Among authors: keller stanislawski b. Allergol Select. 2023 Mar 31;7:90-100. doi: 10.5414/ALX02374E. eCollection 2023. Allergol Select. 2023. PMID: 37056447 Free PMC article.

9

Transdermal nicotine substitution: pharmacokinetics of nicotine and cotinine.

Keller-Stanislawski B, Caspary S, Merz PG, Bonn R, Wolff M, Rietbrock N. Keller-Stanislawski B, et al. Int J Clin Pharmacol Ther Toxicol. 1993 Sep;31(9):417-21. Int J Clin Pharmacol Ther Toxicol. 1993. PMID: 8225689

10

Pharmacokinetic profile of a novel slow release preparation of molsidomine.

Rietbrock S, Keller-Stanislawski B, Thürmann P, Brockmeier D. Rietbrock S, et al. Eur J Clin Pharmacol. 1992;43(3):273-6. doi: 10.1007/BF02333022. Eur J Clin Pharmacol. 1992. PMID: 1425891

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

89 results

Search Page

Filters